KPIs & Operating Metrics(New)
Assets By SegmentBreakdown Of AssetsCapital Expenditure By SegmentContractual ObligationsCost Of Goods SoldDeferred RevenueEmployee StatisticsGross Margin %Gross Margin Annual %Gross ProfitGross Profit AnnualIncome Before Income Tax By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Margin By Segment %Operating Margin By Segment Annual %Operating Profit (Loss) By SegmentOperating Profit (Loss) By Segment AnnualOpex As A % Of Total Revenue %OPEX SegregationProperty And Equipment By GeographyProperty And Equipment, Net BreakdownRevenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Bio-Rad Laboratories (BIO) Gross Profit (2009 - 2026)

Bio-Rad Laboratories (BIO) reported Gross Profit of $309.4 million for Q1 2026, up 1.11% year-over-year from $306.0 million in Q1 2025, and down 10.37% on a QoQ basis from $345.2 million in Q4 2025.

Bio-Rad Laboratories (BIO) has 18 years of Gross Profit data on file, last reported at $309.4 million in Q1 2026.

  • Quarterly Gross Profit rose 1.11% year-over-year to $309.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 1.16% YoY) and the FY2025 annual result came in at $1.3 billion, down 2.83% from the prior year.
  • Gross Profit slipped to $309.4 million in Q1 2026 per BIO's latest filing, from $345.2 million in the prior quarter.
  • Across five years, Gross Profit topped out at $402.6 million in Q1 2022 and bottomed at $306.0 million in Q1 2025.
  • The 5-year median for Gross Profit is $355.1 million (2024), against an average of $354.3 million.
  • The widest annual swing landed in 2022, when Gross Profit dropped 14.64%; it then rose 6.02% in 2024.
  • Tracing BIO's Gross Profit over 5 years: stood at $397.1 million in 2022, then slipped by 7.76% to $366.3 million in 2023, then declined by 6.63% to $342.0 million in 2024, then rose by 0.94% to $345.2 million in 2025, then declined by 10.37% to $309.4 million in 2026.
  • Per Business Quant, the three latest BIO Gross Profit figures stand at $309.4 million (Q1 2026), $345.2 million (Q4 2025), and $343.4 million (Q3 2025).